Repare Therapeutics RPTX 深 滬
等待開盤 10-31 09:30:00 美东时间
1.77
-0.010
-0.56%
華盛通- 最 高1.78
- 今 開1.76
- 成交量 11.88万股
- 最 低 1.72
- 昨 收 1.78
- 總市值 7603.78万
- 52周最高 4.0695
- 市盈率 靜 --
- 換手率 0.28%
- 52周最低 0.89
- 委 比 89.54%
- 總股本 4295.92万
- 歷史最高 46.44
- 量 比 0.57
- 振 幅 3.37%
- 歷史最低 0.89
- 每 手 1
- 風險率 0.67%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
10-28 10:08
HC Wainwright & Co. Maintains Buy on Repare Therapeutics, Lowers Price Target to $3
HC Wainwright & Co. analyst Robert Burns maintains Repare Therapeutics (NASDAQ:RPTX) with a Buy and lowers the price target from $5 to $3.
10-27 21:34
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
RASTherapeutics宣布将于10月20日发布其合作伙伴上海杰优医药开发的RPT904在慢性自发性荨麻疹患者中进行的II期临床试验顶线数据，并举行网络研讨会，提供电话和网络接入方式。公司简介及联系方式随附。
10-19 12:00
Repare Therapeutics To Share Initial Topline Safety, Tolerability And Early Efficacy Data From Phase 1 LIONS Trial In Poster Presentation At AACR-NCI-EORTC International Conference 2025
Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ:RPTX), a clinical-stage precision oncology company, today announced it will share initial topline safety, tolerability and early efficacy data from the Phase 1
10-14 04:06
RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy
RAPT Therapeutics received FDA clearance to initiate a Phase 2b trial for RPT904, a long-acting anti-IgE antibody, targeting food allergies. The trial will compare dosing every 8 or 12 weeks. RAPT expects to start the trial by year-end and anticipates data from Jeyou's Phase 2 studies in chronic urticaria and asthma. RPT904 aims to inhibit IgE, with better pharmacokinetics than first-gen anti-IgE drugs.
09-29 09:00
Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
Rapport Therapeutics announced that its management will participate in TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 17, 2025. The company, focused on developing precision medicines for neurological and psychiatric disorders, will host a fireside chat during the virtual event. Investors can access the webcast on the company’s website. Rapport’s RAP technology platform enables the creation of targeted sma...
09-11 20:05
Rapport Announces Proposed Public Offering of Common Stock
Rapport Therapeutics is conducting a $250 million underwritten public offering of its common stock, with an option for underwriters to purchase an additional $37.5 million. The offering is subject to market conditions and has been filed with the SEC under a shelf registration statement. Rapport Therapeutics focuses on developing small molecule precision medicines for neurological and psychiatric disorders, utilizing its RAP technology platform to...
09-08 20:05
Rapport Therapeutics to Announce Topline Results for RAP-219 Phase 2a Trial in Focal Onset Seizures on Monday, September 8, 2025
Rapport Therapeutics将举行电话会议和网络直播，于9月8日上午8点ET，公布RAP-219治疗难治性局灶性癫痫的IIa期顶线结果。公司聚焦神经及精神疾病精准药物，RAP技术基于受体蛋白，使药物如RAP-219精准作用于大脑特定区域，用于治疗癫痫、双相情感障碍和神经痛等。
09-05 20:05
RAPT Therapeutics Reports Second Quarter 2025 Financial Results
RAPT Therapeutics reported Q2 and H1 2025 financial results, highlighting a net loss of $17.6 million for Q2 and $34.8 million for H1, compared to $27.7 million and $58.2 million in 2024. R&D expenses decreased by $10.3 million and $23.0 million, while G&A expenses increased slightly. The company strengthened its team and pipeline, with plans to initiate a Phase 2b trial for RPT904 in food allergy later this year and report topline results from J...
08-07 12:00
Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update
Rapport Therapeutics reported that the Phase 2a trial of RAP-219 for drug-resistant focal onset seizures is fully enrolled and expects topline results in September 2025. Additionally, the Phase 2 trial for bipolar mania is ongoing with results anticipated in the first half of 2027. The company ended Q2 2025 with $260.4 million in cash, supporting operations through 2026. Second-quarter net loss was $26.7 million, with R&D and G&A expenses increas...
08-07 11:00
